Figure 3
From: Outcome of therapy-related myeloid neoplasms treated with azacitidine
Aberrant karyotype was predictor of death in t-AML, but not in t-MDS patients. Survival was studied according to the presence of any cytogenetic aberrations versus normal karyotype